Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript
Alamar Biosciences (ALMR) reported Q3 2026 revenue growth of 68% YoY, with consumables up 79%. Gross margin improved to 61.5%. The company raised full-year guidance and announced partnerships with U.K. Biobank and GSK, totaling over 140,000 samples. ALMR added 35 publications, bringing the total to over 200, and strengthened its leadership team.
How this was made

The 30-second read
Why it matters
The guidance raise and high‑margin performance provide a catalyst for short‑term price appreciation, while the large study contracts signal longer‑term revenue runway.
Market read
Earnings beat and guidance lift are the primary drivers of market reaction for ALMR.
What to watch
Execution risk of large‑scale studies and potential competition from other proteomics platforms.
Background
Alamar Biosciences reported Q3 2026 results, highlighting rapid revenue growth, margin expansion, and new partnerships with GSK and UK Biobank.
Ticker impact
Q3 2026 earnings call disclosed 68% revenue growth YoY and raised full-year revenue guidance.
likely upside as investors price in higher revenue outlook
Earnings beat and guidance lift are fresh, material information for a small‑cap biotech.
Market effects
Strong results may boost sentiment in the proteomics and biotech sector.
Primarily U.S. biotech investors; limited broader market effect.
Modest, as Alamar is a niche player in low‑abundance protein detection.
Counterpoint
If the partnership deals fail to translate into revenue, the guidance may be overly optimistic.
Key entities
- CompanyAlamar Biosciences
US‑listed biotech developing the NULISA proteomics platform.
- PartnerGSK
Biopharma partner for a 60,000‑sample biomarker study.
- PartnerUK Biobank
Collaborator on an 80,000‑sample neurodegeneration study.


